Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vaccines
BARDA awards Sanofi $226 million for egg-free flu vaccine
by Ryan Cross
December 12, 2019
| A version of this story appeared in
Volume 97, Issue 48
The Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services, has awarded Sanofi Pasteur $226 million to develop egg-free influenza vaccines at its vaccine plant in Swiftwater, Pennsylvania. BARDA says the deal is part of its effort to prepare for the next influenza pandemic. Most flu vaccines are grown in eggs, but Sanofi already sells one biologic flu vaccine, Flublok Quadrivalent, made from recombinant DNA grown in cells.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X